Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis

Table 4 Estimated odds of serious infection for selected^a treatment strategies of interest

Treatment strategy	Comparator	Odds ratio	Standard error	95% Confidence interval
Azathioprine/6MP	Methotrexate	2.75	1.42	0.17	44.07
Prednisone	Azathioprine/6MP	1.34	0.76	0.30	5.96
Infliximab + azathioprine/6MP	Azathioprine/6MP	0.77	0.50	0.29	2.06
Ustekinumab	Natalizumab	0.51	0.63	0.15	1.73
Vedolizumab	Natalizumab	0.95	0.55	0.32	2.76
Golimumab	Natalizumab	2.15	0.77	0.47	9.82
Vedolizumab	Ustekinumab	1.87	0.61	0.56	6.22
Golimumab	Ustekinumab	4.24	0.82	0.84	21.32
Golimumab	Vedolizumab	2.27	0.76	0.51	10.16

Abbreviations: 6MP 6-mercaptopurine
^aOther group comparisons can be found in Additional files 1, 2, 3, 4, 5, 6, and 7

ISSN: 1471-230X